Madrigal Pharmaceuticals Inc
MDGL
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
170.5% upsideUndervalued by 170.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.46 Billion |
|---|---|
| Enterprise Value | $11.58 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-12.85 |
| Beta | -1.05 |
| Outstanding Shares | 29,032,422 |
Return
| Return on Equity | -56.94% |
|---|---|
| Return on Assets | -25.21% |
| Return on Invested Capital | -37.17% |
Valuation & Multiples
| P/E Ratio | -46.66 |
|---|---|
| PEG | -161.54 |
| Price to Sales | 12.52 |
| Price to Book Ratio | 27.12 |
| Enterprise Value to Revenue | 10.23 |
| Enterprise Value to EBIT | -35.04 |
| Enterprise Value to Net Income | -38 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.64 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5371▼ 30.76% |
|---|---|
| Total Calls | 639,401▲ 36.77% |
| Total Puts | 343,400▼ 13.04% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 105.97%▲ 1.14% |
|---|---|
| Total Invested | $12.44B▼ 9.30% |
| Investors Holding | 404▼ 8.00% |
ESG Score
No data
About Madrigal Pharmaceuticals Inc
CEO: Rebecca Taub Relevant Senate Committees
Controls taxation, trade, and entitlement spending (Medicare/Medicaid); directly impacts pharmaceutical company profitability through tax policy and significantly influences drug pricing and reimbursement via healthcare programs.
Directly regulates the FDA (drug approval, safety, manufacturing standards) and influences NIH funding for biomedical research, which are paramount for pharmaceutical development and commercialization.
Oversees antitrust laws and intellectual property; critical for pharmaceutical companies due to patent protection for drugs and influence over mergers and acquisitions within the sector.